TAK:NYE-Takeda Pharmaceutical Co Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 14.82

Change

-0.03 (-0.20)%

Market Cap

USD 46.60B

Volume

1.57M

Analyst Target

USD 23.62
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.77 (+0.39%)

USD 83.17B
HLN Haleon plc

-0.10 (-0.94%)

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

-0.74 (-0.93%)

USD 13.37B
CTLT Catalent Inc

-0.03 (-0.05%)

USD 10.83B
ELAN Elanco Animal Health

+0.36 (+2.52%)

USD 7.15B
BHC Bausch Health Companies Inc

+0.84 (+11.70%)

USD 2.95B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.12 (-1.36%)

USD 2.70B
CPHI China Pharma Holdings Inc

N/A

USD 3.94M
YCBD cbdMD Inc

-0.05 (-9.23%)

USD 1.92M
PBH Prestige Brand Holdings Inc

-0.02 (-0.03%)

N/A

ETFs Containing TAK

1638:TSE 25.17 % 0.00 %

N/A

N/A
1310:TSE 4.71 % 0.00 %

N/A

N/A
1344:TSE 3.32 % 0.00 %

N/A

N/A
JPMV:PA 2.66 % 0.00 %

N/A

N/A
OSXJ:XETRA 2.66 % 0.00 %

N/A

N/A
JPCHBH:SW 1.73 % 0.00 %

N/A

N/A
JPEUBH:SW 1.73 % 0.00 %

N/A

N/A
JPUSBH:SW 1.73 % 0.00 %

N/A

N/A
UEF2:F 1.66 % 0.00 %

N/A

N/A
UEF2:XETRA 1.66 % 0.00 %

N/A

N/A
ADRA 0.00 % 0.30 %

N/A

N/A
HFXJ 0.00 % 0.30 %

N/A

N/A
BSCS Invesco BulletShares 2028.. 0.00 % 0.10 %

-0.02 (-0.75%)

USD 1.93B
ZJPN 0.00 % 0.30 %

N/A

N/A
XZMJ:LSE Xtrackers ESG MSCI Japan .. 0.00 % 0.00 %

-0.28 (-0.75%)

USD 2.21B
CBBB:PA 0.00 % 0.00 %

N/A

N/A
LYY4:F Multi Units France - Lyxo.. 0.00 % 0.00 %

-0.60 (-0.75%)

N/A
XDNE:F db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

-0.12 (-0.75%)

USD 0.04B
XDNY:F Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

-0.23 (-0.75%)

USD 51.19B
CAB3:XETRA 0.00 % 0.00 %

N/A

N/A
J1GR:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-2.63 (-0.75%)

USD 0.17B
JER5:XETRA JPMorgan ETFs Ireland ICA.. 0.00 % 0.00 %

-0.09 (-0.75%)

USD 0.12B
JPNH:XETRA Lyxor UCITS Japan Topix D.. 0.00 % 0.00 %

-1.57 (-0.75%)

USD 0.18B
LCUJ:XETRA Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

-0.15 (-0.75%)

USD 191.96B
LYY4:XETRA Multi Units France - Lyxo.. 0.00 % 0.00 %

-1.38 (-0.75%)

USD 0.58B
SGAJ:XETRA iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

-0.06 (-0.75%)

USD 2.13B
SODJ:XETRA iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

-0.05 (-0.75%)

USD 2.13B
XZMJ:XETRA Xtrackers ESG MSCI Japan .. 0.00 % 0.00 %

-0.23 (-0.75%)

USD 2.01B
1311:TSE Nomura TOPIX Core30 Liste.. 0.00 % 0.00 %

N/A

USD 9.25B
1474:TSE DIAM JPX Nikkei 400 0.00 % 0.00 %

+105.00 (+-0.75%)

USD 284.09B
1475:TSE iShares Core TOPIX ETF 0.00 % 0.00 %

+0.20 (+-0.75%)

USD 1,877.98B
1481:TSE Listed Index Fund Japanes.. 0.00 % 0.00 %

-17.00 (-0.75%)

USD 4.27B
1483:TSE iShares JPX/S&P CAPEX & H.. 0.00 % 0.00 %

-1.00 (-0.75%)

USD 16.13B
1586:TSE Listed Index Fund TOPIX E.. 0.00 % 0.00 %

+20.00 (+-0.75%)

USD 2.72B
1593:TSE MAXIS JPX-Nikkei 400 0.00 % 0.00 %

-205.00 (-0.75%)

USD 835.34B
1651:TSE Daiwa TOPIX High Dividend.. 0.00 % 0.00 %

+5.00 (+-0.75%)

USD 45.77B
1585:TSE Daiwa TOPIX Ex-Financials 0.00 % 0.00 %

+19.00 (+-0.75%)

USD 4.41B
NADA:XETRA Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

-0.61 (-0.75%)

N/A
JPNJPA:SW UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

-0.46 (-0.75%)

USD 109.00B
HJPN:AU BetaShares WisdomTree Jap.. 0.00 % 0.00 %

+0.13 (+-0.75%)

USD 0.15B
IJP:AU iShares MSCI Japan ETF (A.. 0.00 % 0.00 %

-0.60 (-0.75%)

USD 0.58B
EMNJ:F iShares IV PLC - iShares .. 0.00 % 0.00 %

-0.04 (-0.75%)

USD 1.92B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.85% 43% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.85% 43% F 30% F
Trailing 12 Months  
Capital Gain -9.02% 27% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.02% 27% F 14% F
Trailing 5 Years  
Capital Gain -14.78% 50% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.78% 50% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -5.41% 38% F 15% F
Dividend Return -5.41% 38% F 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.01% 88% B+ 70% C-
Risk Adjusted Return -41.58% 19% F 8% B-
Market Capitalization 46.60B 80% B- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.